Tag Archives: Valeant

Valeant Pharmaceuticals International Inc. is becoming the 800-pound gorilla of the TSX — and that should worry index investors

valeant.jpg

Hedge fund investor Bill Ackman is used to taking big bets for big rewards, as he\’s done with Valeant Pharmaceuticals International Inc. Buyers of Canadian index funds may be on a similar thrill ride without knowing it. Valeant is rapidly becoming the 800-pound gorilla from the Standard & Poor\’s/TSX Composite Index, Canada\’s benchmark equity gauge after an acquisition spree supported ...

Read More »

Valeant Pharmaceuticals International Inc wooing Egyptian drugmaker, wants to expand into veterinary medicine

valeant2.jpg

Valeant Pharmaceuticals International Inc. is in talks to obtain one of the largest drugmakers in Egypt to grow in both veterinary and human medicines, based on people with knowledge of the matter. Valeant Pharmaceuticals International Inc CEO primed for more deals Michael Pearson\’s penchant for acquisitions has helped catapult Valeant Pharmaceuticals International Inc. towards the heavyweight ranks from the TSX ...

Read More »

Valeant Pharmaceuticals International Inc CEO primed for more deals

0519valeant.jpg

LAVAL, QUE. C ?Michael Pearson’s penchant for acquisitions has helped catapult Valeant Pharmaceuticals International Inc. towards the heavyweight ranks of the TSX Composite Index, and also the company’s chief executive officer?shows no indications of slowing down the deal flow. Valeant Pharmaceuticals International Inc. is becoming the 800-pound gorilla of the TSX – which should worry index investors Hedge fund investor ...

Read More »

Valeant Pharmaceuticals International Inc in advanced talks to buy Amoun Pharmaceutical Co: sources

0616valeant.jpg

Valeant Pharmaceuticals International Inc. is in advanced negotiations to acquire Egyptian drugmaker Amoun Pharmaceutical Co. because it seeks to expand into emerging markets, based on people with understanding of the matter. The drugmaker, located in Laval, Quebec, may reach a contract with Amoun\’s shareholders in the coming weeks, the folks said, asking not to be identified as the information is ...

Read More »

What Valeant’s soaring stock price isn’t telling you

0618valeant.jpg

You wouldn\’t be able to tell by Valeant Pharmaceuticals International Inc.\’s stock price, but things haven\’t gone exactly according to plan. As new Valeant CFO, merger expert Robert Rosiello prepared to maintain M&A momentum Valeant Pharmaceuticals International Inc\’s new Chief Financial Officer made his mark being an expert in healthcare mergers and acquisitions, and this is exactly what he really ...

Read More »

Valeant Pharmaceuticals International Inc expands in Middle East with $800-million purchase of Amoun

amoun.jpg

LAVAL, Que. – Valeant Pharmaceuticals International, Inc. said it will buy a significant Egyptian pharmaceutical company for about US$800 million as a platform for further expansion in the centre East and North Africa. The Quebec-based company reported?Friday?it features a definite agreement to purchase Amoun Pharmaceutical from Mercury (Cayman) Holdings. Valeant CEO?Michael Pearson said he hopes the organization will be able ...

Read More »

Valeant passes RBC as Canada’s largest company by market value

0723valeant2.jpg

Valeant Pharmaceuticals International Inc., the drugs company on an acquisition streak, surpassed Royal Bank of Canada because the country\’s largest company by market price on the Toronto Stock market. Valeant surged 4.5 percent to $326.10 per share for any market value of $111.3 billion (US$85.7 billion) at 11:21 a.m. in Toronto. That eclipsed Royal Bank\’s $108.3 billion market price, according ...

Read More »

Valeant Pharmaceuticals International Inc topples RBC to emerge as Canada’s most valuable company

0723valeant.jpg

MONTREAL – Valeant Pharmaceuticals International Inc. has surpassed Royal Bank of Canada as the country\’s largest company by market price after shares increased in the wake of solid second quarter results. Valeant surged a lot more than nine per cent to a 52-week-high of $341.02 per share to achieve a market worth of $116.3 billion around the Toronto Stock Exchange, ...

Read More »